Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Analysts Expect Ranbaxy Failure To Benefit From Indian Acquisitions

This article was originally published in PharmAsia News

Executive Summary

Industry analysts say the plan by Ranbaxy Laboratories to buy into other Indian drug makers and suppliers has not yet reaped benefits. Ranbaxy had acquired equity shares in four companies over the past two years to build up its drug pipeline, relying on the addition of the firms' niche products. That effort has failed to produce many results, in part because of the global financial meltdown, analysts said. They believe Daiichi Sankyo, which bought Ranbaxy, has not helped in its dispute with Zenotech Laboratories over the cost of acquiring an additional 20 percent stake. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts